Business Description

Veracyte Inc
NAICS : 325412
SIC : 2834
ISIN : US92337F1075
Compare
Compare
Traded in other countries / regions
VCYT.USA12V.Germany IPO Date
2013-10-30Description
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.86 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -6.76 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 12.34 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.7 | |||||
3-Year EBITDA Growth Rate | 5.2 | |||||
3-Year EPS without NRI Growth Rate | -23.6 | |||||
3-Year FCF Growth Rate | 52.4 | |||||
3-Year Book Growth Rate | 45.8 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.44 | |||||
9-Day RSI | 22.02 | |||||
14-Day RSI | 28.61 | |||||
6-1 Month Momentum % | 19.73 | |||||
12-1 Month Momentum % | 60.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.46 | |||||
Quick Ratio | 4.26 | |||||
Cash Ratio | 3.29 | |||||
Days Inventory | 45.35 | |||||
Days Sales Outstanding | 47.18 | |||||
Days Payable | 41.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.2 | |||||
Shareholder Yield % | 0.18 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 66.91 | |||||
Operating Margin % | -10.2 | |||||
Net Margin % | -8.84 | |||||
ROE % | -2.72 | |||||
ROA % | -2.53 | |||||
ROIC % | -3.56 | |||||
ROC (Joel Greenblatt) % | -61.03 | |||||
ROCE % | -2.62 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.83 | |||||
PB Ratio | 1.47 | |||||
Price-to-Tangible-Book | 7.27 | |||||
Price-to-Free-Cash-Flow | 68.86 | |||||
Price-to-Operating-Cash-Flow | 50.59 | |||||
EV-to-EBIT | -50.84 | |||||
EV-to-EBITDA | -661.4 | |||||
EV-to-Revenue | 4.43 | |||||
EV-to-FCF | 62.88 | |||||
Price-to-Projected-FCF | 2.26 | |||||
Price-to-DCF (FCF Based) | 2.2 | |||||
Price-to-Median-PS-Value | 0.79 | |||||
Price-to-Net-Current-Asset-Value | 8.82 | |||||
Price-to-Net-Cash | 14.17 | |||||
Earnings Yield (Greenblatt) % | -1.97 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VCYT
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Veracyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 328.633 | ||
EPS (TTM) ($) | -0.4 | ||
Beta | 2.06 | ||
Volatility % | 53.25 | ||
14-Day RSI | 28.61 | ||
14-Day ATR ($) | 0.875008 | ||
20-Day SMA ($) | 24.017 | ||
12-1 Month Momentum % | 60.84 | ||
52-Week Range ($) | 14.92 - 32.4 | ||
Shares Outstanding (Mil) | 72.75 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Veracyte Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Veracyte Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Veracyte Inc Frequently Asked Questions
What is Veracyte Inc(VCYT)'s stock price today?
The current price of VCYT is $21.96. The 52 week high of VCYT is $32.40 and 52 week low is $14.92.
When is next earnings date of Veracyte Inc(VCYT)?
The next earnings date of Veracyte Inc(VCYT) is 2023-11-02 Est..
Does Veracyte Inc(VCYT) pay dividends? If so, how much?
Veracyte Inc(VCYT) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |